Gregory Riely, MD
Enriched profileThoracic Medical Oncologist; Vice Chair, Clinical Research, Department of Medicine; Ning Zhao and Ge Li Chair in Lung Cancer Research, Memorial Sloan Kettering Cancer Center · Memorial Sloan Kettering Cancer Center
Gregory Riely is Thoracic Medical Oncologist; Vice Chair, Clinical Research, Department of Medicine; Ning Zhao and Ge Li Chair in Lung Cancer Research, Memorial Sloan Kettering Cancer Center at Memorial Sloan Kettering Cancer Center. OpenAlex indexes 1,302 publications with 96,674 citations (h-index 130); ClinicalTrials.gov lists 9 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Medical Oncology profiles in the findmyKOL directory.
Data verified 25 Aug 2026
Overview
Updated 27 Aug 2026
Gregory Riely, MD, is Thoracic Medical Oncologist at Memorial Sloan Kettering Cancer Center. The public record shows 1,302 publications with 96,674 citations (h-index 130), centered on Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Lung Cancer Diagnosis and Treatment. It also documents an investigator role on 9 registered clinical trials, industry payments reported by 10 companies.
- Most recent indexed publication: 2026 · Journal of clinical oncology
- Top research focus: Lung Cancer Treatments and Mutations
- 9 registered trials on ClinicalTrials.gov
- Open Payments reporting from 10 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 35 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 354.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 9 registered studies on ClinicalTrials.gov. The most recent:
- A Study of Sotorasib in People With Non-Small Cell Lung Cancer
Sponsor: Memorial Sloan Kettering Cancer Center
- A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer
Sponsor: Memorial Sloan Kettering Cancer Center
- RO5126766 for Patients With Advanced KRAS-Mutant Lung Cancer
Sponsor: Memorial Sloan Kettering Cancer Center
Industry payments
Updated 27 Aug 2026
10 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20252 payments
- TAIHO ONCOLOGY, INC.Program year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
33.4%Kinase inhibitor30.6%Tagrisso59%Alecensa13%Everolimus12%Xalkori8%Lorbrena7%Part D<11 patientsOther antineoplastic agents2.8%Lumakras100%Part D<11 patientsMetabolism & gastrointestinal
28.6%Corticosteroid11.3%Prednisone100%Part D≥15 patientsProton pump inhibitor6.5%Pantoprazole Sodium100%Part D≥12 patientsNervous system
13.3%Benzodiazepine7%Alprazolam100%Part D<11 patientsOpioid Agonist4.2%Oxycodone Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 27 Aug 2026
173 congress contributions (2005–2026) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- Impact of DLL3 expression and tumor subtype on response to tarlatamab.
ASCO Annual Meeting
ASCO2026Co-author - A phase 2 basket trial of ado-trastuzumab emtansine for patients with <i>HER2</i> amplified cancers.
ASCO Annual Meeting
ASCO2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Clinical validation of tissue and liquid companion diagnostics for BRAF V600E detection in non-small cell lung cancers from the PHAROS study.
Cancer research communications
Article2026 - Quality of Informed Consent via Telemedicine Compared With In-Person for Clinical Cancer Research.
JCO oncology practice
Article2026 - Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer.
Journal of clinical oncology
Clinical Trial2025
Most-cited works
by citation count (OpenAlex)- 01
- 02Tumor mutational load predicts survival after immunotherapy across multiple cancer typesArticle4,407 citations2019
- 03
- 04
- 05Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung CancerArticle3,411 citations2013
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/gregory-riely-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/gregory-riely-72a4a395
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - X / Twitter
x.com/RielyMD
Mentions by others
where others cite or feature them- Other
cancergrace.org/staff/gregory-j-riely-md-phd-grace-faculty
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancergrace.org ↗ - Other
cancernetwork.com/view/between-the-lines-podcast-mobocertinib-use-in-platinum-pretreated-patients-with-egfr-exon-20-insertion-positive-mnsclc
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancernetwork.com ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
Case Western Reserve University
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - PhD
Case Western Reserve University
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - Board Certified
Internal Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - Board Certified
Medical Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
Editorial & leadership roles
journal and society appointments- Chair
NCCN Guidelines Panel for Non-Small Cell Lung Cancer/Mesothelioma/Thymomas and Thymic Carcinomas
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →prnewswire.com ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
- Excellence in Engagement Award
National Comprehensive Cancer Network (NCCN), 2026 Annual Conference
2026verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →prnewswire.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
Secondary affiliations
appointments beyond the home institution- Professor of Medicine
Weill Cornell Medical College
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vivo.weill.cornell.edu ↗
Media & interviews
press, podcasts and appearances- Guest
"Post AACR Debrief with Dr. Greg Riely," Lung Cancer Considered podcast (IASLC)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →iaslc.org ↗ - Panelist
"Clinical Perspectives on KRAS-Mutant NSCLC" video roundtable, The ASCO Post
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗ - Featured expert
"Targeted Therapy in Non-Small Cell Lung Cancer," Research To Practice video podcast
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →videopodcast.researchtopractice.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Valerie Rusch, MD
Memorial Sloan Kettering Cancer Center
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center